PBAC's latest decision on Deferiprone: Recommended (2017). Considered for Treatment of transfusional iron overload associated with thalassaemia major in patients unable to take or in whom desferrioxamine therapy has proven ineffective.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with thalassaemia major who are unable to take or in whom desferrioxamine therapy has proven ineffective.
Therapy area
Rare disease
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Surrogate
Key trials
LA33-BA
Comparator
deferiprone 500 mg tablets
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; submission was cost-neutral against the current 500 mg tablet listing.